



2024 PHARMACY BENEFIT PROGRAM UPDATES

EFFECTIVE JANUARY 1, 2024

As part of our continuing effort to control pharmacy spend, ClearScript is making the following adjustments to our pharmacy benefit program effective January 1, 2024. These updates are designed to maximize value for our clients, while continuing to provide members access to a wide range of clinically effective prescription therapies.

NEW PRIOR AUTHORIZATION REQUIREMENTS

BRAND NAME	GROUP NAME	NEW PRIOR AUTHORIZATION REQUIREMENT
BYDUREON BCISE	DIABETES - GLP-1	DIAGNOSIS OF DIABETES REQUIRED
BYETTA	DIABETES - GLP-1	DIAGNOSIS OF DIABETES REQUIRED
MOUNJARO	DIABETES - GLP-1	DIAGNOSIS OF DIABETES REQUIRED
OZEMPIC	DIABETES - GLP-1	DIAGNOSIS OF DIABETES REQUIRED
RYBELSUS	DIABETES - GLP-1	DIAGNOSIS OF DIABETES REQUIRED
TRULICITY	DIABETES - GLP-1	DIAGNOSIS OF DIABETES REQUIRED
VICTOZA	DIABETES - GLP-1	DIAGNOSIS OF DIABETES REQUIRED

DRUGS MOVING TO A HIGHER TIER

BRAND NAME	GROUP NAME	2023 TIER	2024 TIER
VICTOZA	DIABETES - GLP-1	TIER 2 - PREFERRED BRAND	TIER 3 - NON-PREFERRED BRAND

DRUGS ADDED TO THE EXCLUSION LIST

BRAND NAME	GROUP NAME	2023 TIER	ALTERNATIVE MEDICATIONS
FLOVENT DISKUS	ASTHMA/COPD	TIER 2 - PREFERRED BRAND	ARNUITY ELLIPTA
LEVEMIR	DIABETES	TIER 2 - PREFERRED BRAND	SEMGLEE YFGN, TRESIBA



DIABETES CLASS - PRIOR AUTHORIZATION AND FORMULARY UPDATE

With continued cost pressure in the Diabetes class, ClearScript will be updating our formulary and utilization management strategies to help mitigate significant rising spend.

Beginning January 1, 2024, a new prior authorization in the GLP-1 class will require a diabetes diagnosis for coverage to apply. The prior authorization review will be administered through the claims adjudication process at the point of sale. While a clinical review submission is generally not required, there may be instances where the pharmacy may need to contact the member's healthcare provider to verify a diabetes diagnosis. These measures are being taken to control off-label use of these medications for weight loss.

If your plan is interested in exploring weight loss coverage strategies, we encourage you to contact your ClearScript Account Team for more information about your plan design and program options.

In addition, ClearScript will be repositioning the diabetes drug Victoza in the non-preferred tier and adding Levemir to the exclusion list. In both cases, clinically effective, lower net cost covered formulary alternatives are available.

OTHER UPDATES

Flovent Diskus, used in the treatment of Asthma and chronic obstructive pulmonary disease, is also being added to the exclusion list. Taking its place in the preferred tier is Arnuity Ellipta, which offers the same clinical advantage at a lower cost to the plan.

MEMBER NOTIFICATION

ClearScript is dedicated to keeping plan members informed about these important changes. We will send notification letters to those with a GLP-1 prescription in their claims history within the last 120 days. We will also send notification letters to members impacted by other formulary updates.

Our Member Services team is always available to provide support and address any questions or concerns from members about these adjustments.

Your Account Team will provide information on any updates that may impact your members.

We look forward to continuing our service to you and your members in 2024.

**For more information about ClearScript's benefit program,
please contact your ClearScript Account Team.**

